Health

Warnings Added to Common Sleep Pills

The Food and Drug Administration (FDA) is requiring a Boxed Warning, the most prominent warning, to be added to certain common prescription insomnia medicines because of sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake. These complex sleep behaviors have also resulted in deaths. These behaviors appear to be more common with eszopiclone (Lunesta), zaleplon (Sonata), and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist) in a class of medicines called sedative-hypnotics than other prescription medicines used for sleep. The FDA is also requiring a Contraindication, the strongest warning, to avoid use in patients who have previously experienced an episode of complex sleep behavior with eszopiclone, zaleplon, and zolpidem. Patients should stop taking your insomnia medicine and contact your health care professional right away if you experience a complex sleep behavior where you engage in activities while you are not fully awake or if you do not remember activities you have done while taking the medicine. All medicines taken for insomnia can impair driving and activities that require alertness the morning after use, even if you feel fully awake. Source: https://www.fda.gov/

hyangiu

Recent Posts

Alcohol Consumption Increases Liver Cancer Risk in Chronic Hepatitis B

Alcohol consumption was independently associated with a substantially higher risk of hepatocellular carcinoma (HCC) among…

2 days ago

Sugar Intake During Antibiotic Treatment May Worsen Gut Microbiome Disruption

Consuming sweets and simple sugars during antibiotic treatment was associated with greater gut microbiome disruption,…

2 days ago

Cancer-Associated Coagulopathy–Related Stroke

A systematic review of 82 studies found that stroke related to cancer-associated coagulopathy (CAC) is…

1 week ago

Ultra-Processed Foods Linked to the Risk of Chronic Diseases

Higher consumption of ultra-processed foods (UPFs) was associated with increased risks of multiple chronic diseases…

2 weeks ago

Effects of Sacubitril/Valsartan Compared With ARBs or CCBs

A meta-analysis of 15 randomized controlled trials involving 4,824 patients with high blood pressure found…

2 weeks ago

Chronic Inflammation: A Common Pathway Linking Genetic and Environmental Cardiovascular Risk

Higher levels of chronic systemic inflammation were associated with smaller left ventricular volumes, compensatory increases…

2 weeks ago

This website uses cookies.